Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

GlobeNewswire December 4, 2023

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

GlobeNewswire November 20, 2023

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

GlobeNewswire November 9, 2023

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

PR Newswire October 30, 2023

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

PR Newswire October 11, 2023

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

Accesswire September 18, 2023

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

GlobeNewswire September 18, 2023

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

GlobeNewswire August 8, 2023

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

GlobeNewswire July 20, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire July 13, 2023

50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis

Accesswire July 12, 2023

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

GlobeNewswire July 10, 2023

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

GlobeNewswire July 6, 2023

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

GlobeNewswire June 28, 2023

Atossa Therapeutics Announces $10M Stock Repurchase Program

GlobeNewswire June 27, 2023

Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023

GlobeNewswire June 22, 2023

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

GlobeNewswire June 21, 2023

Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC

GlobeNewswire June 14, 2023